The haemodynamic effects ofglucagon administered into the pulmonary artery in a single dose of 15, 30, or 45 pg/kg were studied in 9 patients who had coronary heart disease. (Sonnenblick, Parmley, and Matloff, I968). Glucagon has had no significant haemodynamic effect in patients with rheumatic heart disease in chronic congestive heart failure (Greenberg et al., I970) or in the presence of cardiogenic shock (Gregory et al., I969). To elucidate further the potential clinical value of glucagon, the present study was designed to evaluate, at rest and after mild supine leg exercise, the haemodynamic effects of glucagon in patients with coronary heart disease.
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The haemodynamic effects ofglucagon administered into the pulmonary artery in a single dose of 15, 30, or 45 pg/kg were studied in 9 patients who had coronary heart disease. Glucagon did not significantly affect heart rate, cardiac index, left ventricular end-diastolic pressure, or mean brachial artery pressure either at rest or during mild supine leg exercise. The abnormal increase in left ventricular end-diastolic pressure seen in some patients during exercise was not prevented by glucagon administration. A second group of patients underwent two identical periods of exercise separated by a xo-minute period of rest. The changes in the haemodynamic parameters measured were reproducible between exercise periods.
Glucagon has been reported to have significant inotropic effects in various animal preparations (Farah and Tuttle, I960; Glick et al., I968; Regan et al., I964) and in normal subjects or cardiac patients in functional classes i and 2 (Klein, Morch, and Mahon, I968; Linhart et al., I968; Parmley, Glick, and Sonnenblick, I968) . It has been less effective in patients with various myocardial diseases in functional class 3 or 4 (Williams et al., I969) and after aortic or mitral (or both) valve replacement (Sonnenblick, Parmley, and Matloff, I968) . Glucagon has had no significant haemodynamic effect in patients with rheumatic heart disease in chronic congestive heart failure (Greenberg et al., I970) or in the presence of cardiogenic shock (Gregory et al., I969) . To elucidate further the potential clinical value of glucagon, the present study was designed to evaluate, at rest and after mild supine leg exercise, the haemodynamic effects of glucagon in patients with coronary heart disease.
Subjects and methods
Eighteen patients (17 men and i woman), who had severe angina pectoris, were studied at the time of selective coronary arteriography as possible candidates for coronary arterial surgery. The ages of the patients ranged from 35 to 62 years, with a mean of 49 years. All patients were informed of the investigative and elective nature of the study. All patients had angiographic eviReceived 17 January I972.
dence of significant coronary artery disease. None had symptoms of congestive heart failure, and none had cardiomegaly. The studies were performed in the fasting state, after premedication with ioo mg pentobarbitone, and before injection of contrast material. Mean brachial artery pressure, heart rate, cardiac index by the indicatordilution technique, and left ventricular end-diastolic pressure were determined at rest with the patient's feet raised in a bicycle ergometer for 5 minutes and after 3 minutes of supine leg exercise at ioo kg m/min. All patients were then rested for I0 minutes, after which haemodynamic parameters were again measured. Glucagon1 was then injected into the main pulmonary artery of 9 patients. In order to investigate a possible relation between dose and haemodynamic response, a single dose of I5, 30, or 45 ,ug/kg was used. The average individual dose of glucagon was 2-3 mg, with a range of from I 0 to 3-6 mg. Higher dose levels were not investigated because nausea occurred in patients who received 45 ,ug/kg. The same haemodynamic parameters were then measured io minutes after the administration of glucagon and after an identical 3 minutes of supine leg exercise. In order to determine the reproducibility of the haemodynamic changes, the remaining 9 patients underwent a second identical period of exercise after the io-minute rest, without the administration of glucagon.
Results
There were no differences between the untreated group and the group treated with glu- Wiener, Dwyer, and Cox, I968) . This is in contrast to the minor changes in LV enddiastolic pressure (range -3 to +2 mmHg) in normal subjects so stressed (Ross et al., I966) . This abnormal increase in LV enddiastolic pressure has been reported to be partly related to the extent of the coronary artery disease, as judged from coronary arteriograms (Saltups et al., I971) .
The effects of various pharmacological interventions on exercise haemodynamics in patients with coronary artery disease have been reported. Both nitroglycerin (McCallister et al., I968; Wiener, Dwyer, and Cox, I969) and acute digitalization with ouabain (Parker et al., I969) have resulted in significant decreases in LV end-diastolic pressure during exercise, whereas intravenously administered propranolol has had little effect (Parker, West, and Di Giorgi, I968; Wiener et al., I969) . The decreased LV end-diastolic pressure after ouabain was believed to reflect an improvement in left ventricular performance (Parker et al., I969) . It was, therefore, of interest to observe whether glucagon might prevent the abnormal increase in LV enddiastolic pressure with exercise in patients with coronary artery disease by its positive inotropic action. With the doses used in the present study, it was not possible to show a positive inotropic action of glucagon on the exercise-induced abnormalities of left ventricular performance in patients with coronary artery disease. This information may be important to clinicians who hope to obtain benefit from the inotropic activity of glucagon in doses well below that which may be associated with induction of nausea and vomiting. In relation to the previously mentioned studies by Gold et al. (I970) , which may explain differences in response to glucagon of patients in acute or chronic congestive heart failure, it would also be of interest to know whether chronic myocardial ischaemia without gross congestive heart failure might also alter the capacity of glucagon to stimulate adenyl cyclase. 
